<DOC>
	<DOCNO>NCT03071861</DOCNO>
	<brief_summary>This Phase II multicenter placebo-controlled randomize , feasibility/safety trial . Infants &gt; 34 week gestational age perinatal acidemia mild neonatal encephalopathy modify Sarnat neurologic examination less six hour age . Participants randomize receive either one dose Darbepoetin , placebo within 24 hour birth . Neurodevelopmental testing ( Bayley III Gross Motor Function Assessment ) perform 12-18 month age .</brief_summary>
	<brief_title>Mild Encephalopathy Newborn Treated With Darbepoetin</brief_title>
	<detailed_description>Therapeutic hypothermia ( TH ) standard care newborn diagnose moderate severe neonatal encephalopathy ( NE ) presumably due hypoxic ischemia . In order eligible TH infant must perinatal acidemia evidence moderate severe encephalopathy standardize neurologic examination ( Sarnat ) . However , majority newborn perinatal acidemia neurologic examination abnormal enough classified moderate severe NE . In retrospective review , DuPont et al . find many 20 % newborns perinatal academia mild NE abnormal short-term outcome seizure , death progressive asphyxia insult , brain MRI finding consistent NE , abnormal neurologic examination discharge , gastrostomy tube feeding , feed difficulty . Preliminary data prospective trial investigate mild NE ( PRIME study , NCT01747863 ) find 39 % either abnormal electroencephalography &lt; 9h age , abnormal brain MRI finding , abnormal neurological exam discharge . Murray et al . recently report 5-year outcome infant mild encephalopathy show 25 % neurodevelopmental disability . These data suggest mild NE likely carry high risk impair neurological outcome report previously . Thus would appear neuroprotective strategy would beneficial group infant . Preliminary data suggest erythropoiesis stimulate agent ( ESA ) provide neuroprotection , improve short long-term neurologic outcome neonatal brain injury . ESA may work several mechanism include reduced inflammation , limited oxidative stress , decrease apoptosis white matter injury , well via pro-angiogenic neurogenic property . Darbepoetin alfa ( Darbe ) , recombinant human erythropoietin ( EPO ) -derived molecule establish safety pharmacokinetics newborn . Because Darbe extend circulate half-life comparable biological activity EPO , advantage require le frequent administration</detailed_description>
	<mesh_term>Brain Diseases</mesh_term>
	<mesh_term>Brain Ischemia</mesh_term>
	<mesh_term>Hypoxia-Ischemia , Brain</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Infants eligible MEND trial gestational age &gt; 34 week best obstetric estimate , &lt; 24 hour old evidence mild encephalopathy define Shankaran et al base modified Sarnat examination perform &lt; 6 hour age . 1 . History acute perinatal event ( abruption , cord prolapse , severe fetal heart rate abnormality , meconium stain ) 2 . Infant evaluate hypothermia therapy DOES NOT meet clinical criterion TH . 3 . Infant IV clinical treatment 1 . Moderate/Severe encephalopathy modify Sarnat examination &lt; 6 hour age 2 . Major congenital and/or chromosomal abnormality 3 . Prenatal diagnosis brain abnormality hydrocephalus 4 . Severe growth restriction ( &lt; 1800g ) 5 . Central venous hematocrit &gt; 65 % , platelet count &gt; 600,000/dL , and/or neutropenia ( ANC &lt; 500 Î¼L ) 6 . Maternal history major vascular thrombosis multiple fetal loss ( &gt; 3 spontaneous abortion ) 7 . ECMO 8 . Infant judge critically ill unlikely benefit neonatal intensive care attend neonatologist</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>24 Hours</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>darbepoetin</keyword>
	<keyword>Brain Diseases</keyword>
</DOC>